CAY10535 is primarily utilized in research settings as a selective inhibitor of the enzyme soluble epoxide hydrolase (sEH). This enzyme plays a significant role in metabolizing epoxyeicosatrienoic acids (EETs), which are known for their anti-inflammatory and vasodilatory properties. By inhibiting sEH, CAY10535 helps in increasing the levels of EETs, thereby potentially reducing inflammation and improving vascular function. This makes it a valuable compound in studies focused on understanding and treating conditions such as hypertension, atherosclerosis, and other inflammatory diseases. Additionally, its application extends to investigating the role of sEH in pain management and neuroprotection, offering insights into novel therapeutic strategies for these areas.